Navigation Links
Ceragenix Announces New Publication of Scientific Research on,Ceragenin Technology

DENVER--(BUSINESS WIRE)--Apr 23, 2007 - Ceragenix Pharmaceuticals, Inc. (OTCBB:CGXP), a biopharmaceutical company focused on infectious disease and dermatology, today announced the publication of a research paper on two of the Company's antimicrobial compounds: CSA-8 and CSA-13. The paper appeared in the April issue of the Journal of Antimicrobial Agents and Chemotherapy, a peer-reviewed official Journal of the American Society of Microbiology, dedicated to advances in the field of applied microbiology.

The publication is entitled "Antimicrobial Activities of Ceragenins Against Clinical Isolates of Resistant Staphylococcus Aureus" authored by Drs.Chin, Rybak, Cheung and Savage (Drs. Chin, Rybak and Cheung are researchers at the Anti-Infective Research Laboratory of the Eugene Appelbaum College of Pharmacy and Health Sciences, Wayne State University and Dr. Savage is the Reed Izatt Professor of Chemistry and BioChemistry at Brigham Young University). Dr. Savage is the inventor of the Ceragenin(TM) technology and also serves as a consultant to the Company. The authors highlight the need for development of new antimicrobial compounds to combat the rising incidence of strains of Staphylococcus Aureus that are now resistant to methicillin (MRSA) and vancomycin (VISA, hVISA and VRSA) antibiotics and describe the potent in vitro activity of CSA-8 and CSA-13 against such strains. The authors concluded that:

"Ceragenins are unique, low-molecular-mass compounds that have potent bactericidal activities against both gram-negative and gram-positive bacteria, particularly clinically relevant pathogens such as MRSA .... Both CSA-8 and CSA-13 are promising antimicrobials and may have important therapeutic implications for infections caused by hVISA and VISA strains. Given that these small compounds are experimental antimicrobial agents, future safety, efficacy and pharmokinetic studies in vivo should be performed to cor
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Ceragenix Compound Shows Promise for Treating Lethal Cystic Fibrosis Infections
2. Ceragenix Announces Results from Phase IV Study of EpiCeram Meet All Primary and Secondary Endpoints
3. Ceragenix Announces Ceragenins Virtually Prevent Catheter Biofilm Formation in 21 Day Study
4. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
5. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
6. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
7. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
8. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
9. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
10. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
11. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
Post Your Comments:
Breaking Medicine Technology:Octapharma USA Announces FDA Approval of wilate(R) - the First Replacement Therapy Developed Specifically for von Willebrand Disease 2Octapharma USA Announces FDA Approval of wilate(R) - the First Replacement Therapy Developed Specifically for von Willebrand Disease 3Octapharma USA Announces FDA Approval of wilate(R) - the First Replacement Therapy Developed Specifically for von Willebrand Disease 4Octapharma USA Announces FDA Approval of wilate(R) - the First Replacement Therapy Developed Specifically for von Willebrand Disease 5Stallergenes: Oralair: Very Positive 3-Year Results of the Long-Term Study 2Stallergenes: Oralair: Very Positive 3-Year Results of the Long-Term Study 3Stallergenes: Oralair: Very Positive 3-Year Results of the Long-Term Study 4Stallergenes: Oralair: Very Positive 3-Year Results of the Long-Term Study 5Q-Med AB and Oceana Therapeutics, Inc. Take Major Step Towards SOLESTA(TM) US Regulatory Filing 2Q-Med AB and Oceana Therapeutics, Inc. Take Major Step Towards SOLESTA(TM) US Regulatory Filing 3Sysmex America Receives Highest Vendor Designation from MedAssets Supply Chain Systems 51679 1Sysmex America Receives Highest Vendor Designation from MedAssets Supply Chain Systems 51679 2FRCs Tony Perkins Commends Pro life Lawmakers Who Oppose Federal Funding of Abortion 51676 1FRCs Tony Perkins Commends Pro life Lawmakers Who Oppose Federal Funding of Abortion 51676 2Sono Tek Announces First Quarter Results 51672 1Sono Tek Announces First Quarter Results 51672 2Sono Tek Announces First Quarter Results 51672 3